Phase 1b

DRUG3 trials

Sponsors

Actelion, Chemocentryx, Regeneron Pharmaceuticals, Inc.

Conditions

Glioblastomaalvleesklier pancreatic adenocarcinoma Pancreatic cancermelanoma unresectable melanoma

Phase 1

Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma

TerminatedNCT01499251

ActelionGlioblastoma

Start: 2012-01-31End: 2016-04-30Target: 75Updated: 2016-05-05

Unknown Phase

An open-label phase 1b study to evaluate the safety and efficacy of CCX872-B in patients with pancreatic adenocarcinoma.

Active, not recruitingNL-OMON42021

Chemocentryxalvleesklier pancreatic adenocarcinoma Pancreatic cancer

Start: 2015-04-20Target: 29Updated: 2024-02-28

An exploratory tumor biopsy-driven study to understand the relationship between biomarkers and indicators of clinical response in immunomodulatory treatment naïve unresectable stage III/IV melanoma patients receiving REGN2810 (anti-PD-1)

Active, not recruitingNL-OMON49259

Regeneron Pharmaceuticals, Inc.melanoma unresectable melanoma

Start: 2018-03-07Target: 8Updated: 2024-02-28

Related Papers

Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma

Neuro-Oncology Advances2021-01-015 citations